Today Pyreos announced that due to significant market growth, as well as major yield and cost improvements, it has reduced the volume price of its 128 pixel linear array product line by 50%.

This is the steepest price reduction in the company’s history and enables customers to offer spectrometers for use in market segments previously considered too price sensitive for this high-end technology.  Pyreos linear array prices will now fall below $900 at volumes of 500 units.

The new pricing applies to all Pyreos 128 pixel products: PY1499 (2.5µm-5 µm), PY0738 (5.5µm-11 µm), PY2004 (5.5µm-11 µm + high SNR fat analysis pixel), PY2075 (5.5µm-11 µm + high SNR oil analysis pixel).

Today’s news will give Pyreos customers exciting possibilities for building systems suited to a range of applications including food safety, lubrication, oil and fuel testing for engine efficiency and preventative maintenance, in-line process monitoring, and medical testing in the home.

Pyreos 128 linear array components are often referred to as “spectrometer on a chip” and offer high performance right across the infrared spectrum, particularly in the mid-infrared. The new pricing model coupled with unique features such as fast response and instant start-up, low power consumption, high responsivity and thermal stability, means they provide a radical low-cost alternative for building IR spectrometers and spectral analysers. Compared with traditional moving-mirror systems, Pyreos-based solutions are more robust because they have no moving parts and cover wider wavelength ranges with one instrument which allows a more complete analysis of the sample.  The product families are also sold with the rights to use the Pyreos patented ATR system as well as extensive design tools and support services.

“We are delighted to announce these dramatic price adjustments for our leading linear arrays,” said Andrew Wallace, CEO at Pyreos. “Companies such as Ocean Optics, Parker Kittiwake and Bosch are all using these products for fast and accurate mid-IR analysis in several applications. Meanwhile Bill Gates’ Global Good Fund has published the suitability of this device for milk testing in low-income markets, and the first low-cost clinical-grade spectrometer has been developed for sputum analysis, aimed at identifying lung conditions. It’s this strong market momentum that has allowed such a major price cut and we hope to see a continued trend towards higher volumes as the technology is adopted across more analyser markets.”